Gene signature predicts severe adverse events from ICI therapy for melanoma
Source: Healio, August 2024
Key takeaways:
- The spleen tyrosine kinase pathway was upregulated in patients that had severe toxicities from immune checkpoint inhibitor therapy.
- This signature accurately identified 60% of patients with toxicities.
Researchers identified a gene signature that can predict which group of patients with melanoma will experience severe immune-related adverse events when treated with immune checkpoint inhibitor therapy, according to a study.
“Immune checkpoint inhibition (ICI) therapies, combining the two antibodies anti-PD-1 and anti-CTLA-4, is an approved frontline therapy with the highest clinical efficacy for treating melanoma,” Tomas Kirchhoff, PhD, associate professor in the department of population health at NYU Langone Health, researcher at Perlmutter Cancer Center and an investigator of this study, told Healio. “However, they are associated with significant immune-related toxicities, which may be a major clinical problem.”